News
MIRM
89.70
+0.38%
0.34
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
Seeking Alpha · 19h ago
Mirum Pharmaceuticals, Incyte announce FDA approval of Atebrioz
TipRanks · 1d ago
3 things to look out for on Friday
Seeking Alpha · 2d ago
Weekly Report: what happened at MIRM last week (0914-0918)?
Weekly Report · 5d ago
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
Seeking Alpha · 09/18 19:10
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
Seeking Alpha · 09/16 16:12
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst
Seeking Alpha · 09/15 13:19
Weekly Report: what happened at MIRM last week (0907-0911)?
Weekly Report · 09/14 10:29
Mirum’s AZURE-3 Trial: A New Switch Strategy in Chronic Hepatitis D
TipRanks · 09/10 16:31
Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
TipRanks · 09/10 10:20
Mirum Pharmaceuticals Announces New Chief Medical Officer Appointment
TipRanks · 09/08 12:59
Mirum Pharmaceuticals appoints Myers as Chief Medical Officer
TipRanks · 09/08 12:35
Weekly Report: what happened at MIRM last week (0831-0904)?
Weekly Report · 09/07 10:22
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Barchart · 09/02 15:01
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 08/31 18:57
Weekly Report: what happened at MIRM last week (0824-0828)?
Weekly Report · 08/31 10:30
Mirum Pharmaceuticals Price Target Maintained With a $137.00/Share by Citizens
Dow Jones · 08/27 14:12
Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Benzinga · 08/27 14:01
Biotech Stocks Facing FDA Decision In September 2026
NASDAQ · 08/26 15:11
Weekly Report: what happened at MIRM last week (0817-0821)?
Weekly Report · 08/24 10:30
More
Webull provides a variety of real-time MIRM stock news. You can receive the latest news about Mirum Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.